Yutaka Yamamoto

Professor

Kumamoto University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

LinkedIn

Google Scholar

About

Yutaka Yamamoto is a Professor at Kumamoto University, Japan. His research focuses on breast cancer, particularly on topics such as HER2-positive advanced breast cancer treatment, clinical practice guidelines, and the role of macrophages in cancer progression. He has contributed significantly to studies analyzing treatment protocols and prognostic factors in metastatic breast cancer.

Articles (11)

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

Year:

2025

Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

Year:

2024

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment

Year:

2024

Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes

Year:

2023

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

Year:

2023

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Year:

2023

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Year:

2022

Predictive and prognostic significance of BRCAness in HER2-negative breast cancer

Year:

2022

Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum

Year:

2021

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

Year:

2021

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study

Year:

2020

Collaborators (5)

norikazu masuda

Professor

Nagoya University Graduate School of Medicine

JAPAN

Shigehira Saji

Fukushima Medical University

JAPAN

Masato Takahashi

Professor

Hokkaido University Hospital

JAPAN

Sadako Akashi-Tanaka

Professor

Tokyo Women's Medical University

JAPAN

Yukio Fujiwara

-

JAPAN

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI